INFEX Therapeutics awarded Biomedical Catalyst grant for COV-X project

Alderley Park, Cheshire, U.K – Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18 month, £1m COV-X project, titled: “Optimisation o...

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme

Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive d...

MicroBioSensor launches QUICKCHECK™ designed in partnership with Smallfry

A device that can help speed the diagnosis of peritonitis in vulnerable kidney and liver failure patients. With results 10,000x faster than current methods, this portable and rapid detection device now means that nurses can carry out an instant le...

iiCON to expand pipeline following Research England funding boost

The outstanding results being achieved by the Infection Innovation Consortium – iiCON – have been acknowledged today, with £1.7 million of additional funding from Research England confirmed. Led by Liverpool School of Tropical M...

Monument Therapeutics announces the start of its first clinical study for novel treatment for neuroinflammation

Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel formulation of an on-market anti-inflammatory compound, has commenced. MT1980 has been...

From our portfolio


Digital Healthcare Technology

viewview our portfolio

Our Team

Corinne Lawrence

view complete team

Contact us

Tel: 01625 344300